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Abstract
Heterologous vaccination based on priming with a plasmid DNA vector and boosting with an attenuated vaccinia virus MVA
recombinant, with both vectors expressing the Leishmania infantum LACK antigen (DNA-LACK and MVA-LACK), has shown
efficacy conferring protection in murine and canine models against cutaneus and visceral leishmaniasis, but the immune
parameters of protection remain ill defined. Here we performed by flow cytometry an in depth analysis of the T cell
populations induced in BALB/c mice during the vaccination protocol DNA-LACK/MVA-LACK, as well as after challenge with
L. major parasites. In the adaptive response, there is a polyfunctional CD4
+ and CD8
+ T cell activation against LACK antigen.
At the memory phase the heterologous vaccination induces high quality LACK-specific long-term CD4
+ and CD8
+ effector
memory cells. After parasite challenge, there is a moderate boosting of LACK-specific CD4
+ and CD8
+ T cells. Anti-vector
responses were largely CD8
+-mediated. The immune parameters induced against LACK and triggered by the combined
vaccination DNA/MVA protocol, like polyfunctionality of CD4
+ and CD8
+ T cells with an effector phenotype, could be
relevant in protection against leishmaniasis.
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Introduction
Leishmaniasis is one of the most neglected tropical diseases,
prevalent in 88 countries presenting an estimated annual incidence
of 2 million infections and about 12 million cases worldwide [1].
There are few drugs for chemotherapy available and treatments
are still long-lasting, highly toxic and expensive. The goal in
chemotherapy still remains a safe cheap oral drug and this
objective appears to be distant for both major forms of the disease
[2]. All these evidences point out the development of an effective
vaccine as a major need against leishmaniasis.
Several antigens and different vaccination procedures pursuing
the development of a protective Th1 response against the parasite
have been used in experimental vaccination trials in murine and
canine leishmaniasis achieving varied protection levels [3]. Among
all leishmania antigens used, studies comparing DNA vaccine
candidates pointed out that one of the most promising genes is
LACK [4]. LACK, the leishmania homologue for receptors of
activated C kinase, is a 36 kDa intracellular protein that is
expressed in both stages of the parasite (amastigote and
promastigote) [5], is highly conserved among Leishmania species
[6] and is also very immunogenic, being a preferential target for
the early anti-parasite immune response. In the context of a natural
infection, the early-activated LACK reactive cells exhibit a marked
Th2 phenotype [7]. Some evidences pointed that this immune
profile against LACK antigen can be altered, and this alteration is
enough to induce resistance to infection [8].
T cells have a central function in protection against a broad
range of pathogens. In particular, CD4
+ and CD8
+ T cells can be
important in controlling disease development [9]. In the case of
leishmaniasis, several studies have been performed to dissect the
relevance of CD4
+ and CD8
+ T cell subsets and their relative role
in natural infection [10,11,12,13,14], prophylaxis [15,16,17] or
therapy [18]. However, due to the heterogeneity of T cell cytokine
responses generated by different vaccines, there are still few
defined immune correlates of protection for infections requiring T
cell responses. Consequently, it is of a high importance to improve
the understanding of functional heterogeneity of CD4
+ and CD8
+
T cell cytokine responses induced by the current vaccine
candidates [15].
We have previously described that vaccination with DNA-
LACK and MVA-LACK was able to confer protection against
cutaneus leishmaniasis in BALB/c mice after challenging the
animals with metacyclic promastigotes [19] and against visceral
leishmaniasis in dogs [20]. In both cases protection was mediated
by a Th1-like immune response against LACK antigen. However,
a deep study of the immune populations involved in protection was
still needed.
Multicolor Flow Citometry is a powerful tool to discriminate
between different immune populations as it evaluates magnitude
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38859and quality of cellular responses [21]. In this work we analyzed by
Intra Cellular Staining (ICS) the adaptive and memory T cell
responses induced by prime/boost vaccination with DNA-LACK/
MVA-LACK using markers that recognize T cell lineages (CD4,
CD8), T cell functions (IFNc, TNFa, IL-2) and memory stages
(CD44, CD62L, CD127). In addition, we examined the impact of
the challenge with purified metacyclic promastigotes in those T
cell populations.
Results
DNA-LACK/MVA-LACK induces an adaptive antigen-
specific T cell response mediated by CD4
+ and CD8
+ T
cells with high polyfunctional profile
We have previously described a heterologous prime/boost
vaccination approach based on DNA and vaccinia virus vectors
that induced protection against L. major infection in immunized
BALB/c mice and this effect was Th1-dependent [19]. To analyze
in more detail the vaccine-specific immune responses triggered in
BALB/c mice by a DNA-LACK/MVA-LACK immunization
regimen, groups of mice were first primed intradermally (i.d.) with
100 mg of DNA-LACK or sham DNA (DNAw), and two weeks
later the animals were boosted by intraperitoneal (i.p.) route with
2610
7 PFU/mouse of recombinant virus MVA-LACK or MVA-
wt. Vaccine-elicited adaptive immune responses using splenocytes
stimulated in vitro with either purified LACK protein or LACK157–
173 peptide, were measured 11 days after the boost by fresh IFNc
ELISPOT and ICS assays. The number of IFNc secreting cells
detected against both stimulus was significantly increased in the
group of animals that received DNA-LACK/MVA-LACK in
comparison with control group (DNAw/MVA-wt) (Fig. 1A).
To study the contribution of CD4
+ and CD8
+ T cell subsets in
the overall LACK-specific immune responses, the sum of the
frequency of antigen-specific T cells secreting IFNc and/or IL-2
and/or TNFa was determined. At 11 days post-boost, there was
a specific induction of CD4
+ and CD8
+ T cells in the group that
received DNA-LACK/MVA-LACK in comparison with animals
immunized with DNAw/MVA-wt (Fig. 1B).
The simultaneous measurements of three cytokines allowed the
assessment of the quality of the vaccine-induced CD4
+ and CD8
+
T cell responses. On the basis of the analysis of IFNc, TNFa and
IL-2 secretion, seven distinct LACK-specific CD4
+ and CD8
+ T
cell populations were identified. As shown in Fig. 1C, the
heterologous vaccination protocol DNA-LACK/MVA-LACK
induces CD8
+ T cells represented mainly by single positive cells
secreting IFNc or TNFa. However, around 78% of vaccine-
induced CD4
+ T cells showed high polyfunctional profile
represented by T cells secreting three cytokines (43.19%), or two
cytokines (34.81%) (Fig. 1D).
We also analyzed in more detail the phenotype of the adaptive
immune response against LACK157–173, a crucial CD4
+ T cell
restricted peptide involved in the development of a Th2 response
and susceptibility [22]. To this end, we evaluated the frequency of
IFNc, TNFa and/or IL-2 secreting cells after in vitro stimulation
with LACK157–173 peptide. As expected, CD4
+ T cells mediated
the overall peptide-specific immune responses whereas no specific
CD8
+ T cell responses were detected. The vaccine-induced CD4
+
T cell responses detected against LACK157–173 peptide at 11 days
after the boost were highly polyfunctional with more than 75% of
cells secreting 2 (36.12%) or 3 (43.78%) cytokines (Fig. 1E).
As it has been previously shown by others [15], there is
a correlation between levels of secretion of cytokines and
Fluorescence Intensity, thus we next measured the geometric
Mean of Fluorescence Intensity (gMFI) within the different
populations of LACK-specific CD4
+ T cells. As a result, triple
positive CD4
+ T cells had a 3.28 fold increase in gMFI for IFNc,
2.56 in the case of TNFa or 2.66 for IL-2 in comparison with
single cytokine secreting cells (Fig. 1F).
The above findings showed that during adaptive immune
responses the protocol DNA/MVA triggered CD4
+ and CD8
+ T
cells that are polyfunctional.
Effector memory CD4
+ and CD8
+ T cells with
a polyfunctional profile are elicited by the heterologous
DNA-LACK/MVA-LACK vaccination
Since memory T cell responses are critical to induce long-term
protection against infection, we assessed at 53 days post-boost the
memory profile elicited by DNA-LACK/MVA-LACK immuni-
zation. Vaccine-elicited memory immune responses in splenocytes
from immunized animals stimulated with LACK protein or
LACK157–173 peptide were first measured by IFNc ELISPOT
assay. As shown in Fig. 2A, DNA-LACK/MVA-LACK regimen
induces strong and long-lasting antigen-specific IFNc responses
while in DNAw/MVA-wt no antigen-specific responses were
detected. The overall LACK-specific immune response at 53 days
post-boost was mainly mediated by both CD4
+ and CD8
+ T cells
(Fig. 2B).
To evaluate in more detail the phenotype of the LACK-specific
memory T cells elicited by the immunization DNA/MVA
protocol, splenocytes were stained for CD4, CD8, CD44 and
CD62L surface markers in order to differentiate between the
different memory populations. With those markers we can
distinguish naı ¨ve (CD442 CD62L
+), central memory (CD44
+
CD62L
+) and effector memory T cells (CD44
+ CD62L
2). We also
evaluated by ICS IFNc, TNFa and IL-2 secretion after in vitro
stimulation with purified LACK protein or LACK157–173 peptide.
Both CD4
+ and CD8
+ antigen-specific T cell responses have
mainly an effector phenotype. As in the acute phase, at day 53 the
heterologous vaccination induced CD4
+ T cells that showed a high
polyfunctional profile with T cells secreting three cytokines
(29.10%) or different combinations of double positive secreting
cells (38.46%) (Fig. 2C). Memory CD4
+ T cells activated by the
LACK157–173 peptide were also polyfunctional. More than 50% of
the CD4
+ T cells secreted two or more cytokines (33.73% of
double positive or 32.82% of triple positive cells) (Fig. 2D). A
major increase in TNFa single producers was observed in the
specific-responses against both stimulus, being a 31,32% of the
total CD4
+ T cell response. The majority of the CD8
+ T cell
responses were represented by double cytokine producers
(69.40%) while 21.72% were single TNFa producers (Fig. 2E).
In addition to CD62L and CD44 markers we considered
staining the cells for CD62L and CD127 in order to determine
whether effector cells at memory stage were indeed activated
effector T cells (CD62L
2CD127
2) or effector memory T cells
(CD62L
2CD127
+). We also evaluated by ICS IFNc, TNFa and
IL-2 secretion after in vitro stimulation with purified LACK protein
or LACK157–173 peptide. As depicted in Fig S1 both CD4
+ and
CD8
+ antigen-specific T cell responses have mainly a memory
effector phenotype, with 81.8% of CD4
+ and 61% of CD8
+ of
LACK-specific T cells secreting cytokines rare evealing
a CD62L
2CD127
+ phenotype. Similar results (87.2%) were
observed in CD4
+ T cells re-stimulated with LACK157–173 peptide.
The above findings showed that, at the memory phase, both
polyfunctional CD4
+ and CD8
+ T cells with an effector memory
phenotype are activated by the DNA/MVA protocol.
Immune Response Elicited by DNA-LACK/MVA-LACK
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e38859Figure 1. Adaptive immune response induced in mice immunized with the LACK vectors. A. Analysis of the antigen-specific IFNc secreting
cells by splenocytes measured by ELISPOT 11 days after boost. B. Analysis of the total magnitude of CD4
+ and CD8
+ T cell responses in splenocytes re-
stimulated with LACK protein. Among the lymphocyte population, T cells were gated and analyzed for IFNc, TNFa and/or IL-2 production. MVA-wt
background was subtracted before representation. Cytokine production by LACK-specific CD8
+ T cells (C), LACK-specific CD4
+ T cells (D) or LACK157–
173 peptide-specific CD4
+ T cells (E). The different combinations of cytokines are indicated on the x-axis; percentages of T cells producing any cytokine
are indicated on the y-axis. The different pies show the quality of the response measured as the relative quantity of single, double or triple cytokine
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+ and CD8
+ T cells are elicited by DNA-
LACK/MVA-LACK vaccination at early stages after
infection with metacyclic promastigotes of L.major
To evaluate further the immune response to the combined
DNA/MVA vaccine, we next determined the impact of a challenge
infection on the immunological response in vaccinated mice. Thus,
3 groups of animals (4 animals per group) immunized with DNA-
LACK/MVA-LACK, DNAw/MVA-wt or PBS/PBS regimens,
were infected with 5610
4 PNA purified L.major promastigotes 3
weeks after the booster, and 10 days after parasite challenge the
animals were sacrificed and cellular immune responses were
evaluated by ELISPOT and ICS. The parasite infection showed
an ELISPOT profile of IFNc secreting LACK-specific splenocytes
(Fig. 3A) somewhat similar to that observed at pre-challenge
(Fig. 1A). We next dissected the T cell responses by ICS. In
animals vaccinated with DNA-LACK/MVA-LACK there is
a significant increase in both CD8
+ and CD4
+ LACK-specific T
cells frequencies measured as the sum of the frequency of antigen
specific T cells secreting IFNc and/or IL-2 and/or TNFa
compared with the control groups (Fig. 3B). Both CD4
+ and
CD8
+ T cell responses showed high polyfunctionality with 75.43%
of CD4
+ T cells (Fig. 3C) and 49.15% of CD8
+ T cells producing 2
or 3 cytokines (Fig. 3E). CD4
+ T cell (Fig. 3C) have a remarkable
percentage of specific T cells secreting 3 cytokines (38.26%), or
different combinations of double positive secreting cells (45.47%)
when stimulated with LACK protein, and 51,48% of triple
positive and 32% of double positive T cells when restimulated with
LACK157–173 peptide (Fig. 3D). CD8
+ LACK-specific T cell
responses (Fig. 3E) were distributed in two different populations:
IFNc
+/TNFa
+ double positive cells (45.80%) or single IFNc
+
secreting cells (48,40%). Low or undetectable antigen-specific T
cell responses were registered in DNAw/MVA-wt or PBS/PBS
control groups, indicating that the parasite did not elicit LACK-
specific Th1 T cell responses. Splenocytes were also stimulated
with LSA to assess overall T cell responses against the parasite.
LSA-specific T cell responses were mainly represented by CD8
+ T
cells (Fig. S2A). Both CD8
+ and CD4
+ T-cell populations showed
a low polyfunctional profile and were mainly represented by single
IFNc secreting cells (Fig. S2B and S2C).
The findings of Fig. 3 revealed that both CD4
+ and CD8
+ T
cells with a polyfunctional profile are activated in DNA/MVA
vaccinated animals after challenge with L. major at the acute phase
after infection.
As it has been reported previously [23], the development of
lesions in the foodpad of animals infected with L. major takes
approximately 4 weeks. At that point vaccinated animals heal
small swelling lesions and control animals develop cutaneous
disease. To evaluate the state of the immunological response in
vaccinated mice, 2 groups of animals (3 animals per group)
receiving DNA-LACK/MVA-LACK or PBS/PBS, were infected
with 5610
4 PNA purified L. major promastigotes 3 weeks after the
booster, and 28 days after parasite challenge, the animals were
sacrificed and cellular immune responses were evaluated by
ELISPOT and ICS. The parasite infection showed an ELISPOT
profile of LACK-specific IFNc-secreting splenocytes (Fig. S3A)
similar to that observed at pre-challenge (Fig. 1A), or 10 days
postchallenge (Fig. 3A). Hence, the parasite challenge has little
effect on boosting IFNc response acquired by the heterologous
DNA/MVA vaccination approach; notwithstanding this IFNc
response is maintained with time in infected animals.
We next dissected the T cell responses by ICS. In animals
vaccinated with DNA-LACK/MVA-LACK there is an increase in
LACK-specific CD8
+ T cell frequencies measured as the sum of
the frequency of antigen-specific T cells secreting IFNc and/or IL-
2 and/or TNFa (Fig. S3B). CD4
+ T cell responses showed high
polyfunctionality, with 74.9% of cells producing more than two
cytokines; 37,47% were double and 37.43% triple positive (Fig.
S3C). LACK-specific CD8
+ T cell responses were distributed in
two different populations: IFNc
+/TNFa
+ double positive cells
(25.98%) or single IFNc
+ secreting cells (58.75%) (Fig. S3D). Low
or undetectable LACK-specific responses were registered in
control groups. The findings of Fig. S3 revealed that polyfunc-
tional CD4
+ and CD8
+ T cells activated in DNA/MVA
vaccinated animals are maintained with time after challenge with
L. major.
Anti-vector immune responses in vaccinated mice are
mainly polyfunctional CD8
+ T cells
To further characterize the immune responses induced in mice
immunized with DNA-LACK/MVA-LACK, it was of interest to
evaluate the responses against the MVA vector. Thus, we
measured both antibodies and T cell responses in the group of
mice immunized as in Figs. 1 and 2. IgG responses to vaccinia
virus vector were observed in the group of animals vaccinated with
DNA-LACK/MVA-LACK and DNAw/MVA-wt at prechal-
lenge, postchallenge and memory phases (Fig. 4A). Similar levels
were observed at postchallenge and memory phases, indicating the
stability of anti-vaccinia antibodies in the blood serum.
The cellular response to the vector was evaluated by ELISPOT
after splenocyte stimulation with a vaccinia virus specific T cell
peptide, corresponding to the virus E3 protein. The E3 peptide is
one of the most immunogenic vaccinia peptides in BALB/c mice
[24]. The main increase of E3-specific IFNc T cells was observed
at the memory phase (Fig. 4B). By ICS the majority of the anti-
vector T cells were of CD8
+ phenotype, with higher magnitude
and polyfunctional profile at memory phase than at 11 days after
booster (Fig. 4C).
The above findings showed that both humoral and T cell
responses to VACV are induced by the DNA-LACK/MVA-
LACK protocol and anti-vector CD8
+ T cells are preferentially
induced.
Discussion
The LACK antigen is one of the most extensively studied
proteins of Leishmania, because when it is administered as a DNA
vector, as a protein or in combination with cytokines or in
heterologous prime/boost protocols with viral vectors, induced
protection against parasite challenge in mice and dogs [20,25,26].
Since it has been proposed that the quality of a CD4
+ T cell
cytokine response can be a crucial determinant in whether
a vaccine is protective [15], we have defined in this investigation
the immunological profile of cellular responses induced in
heterologous DNA-LACK prime and MVA-LACK boost vacci-
nation approach in mice. We have previously shown efficacy of
this protocol against L. major in mice and dogs [19,20] and
protection levels in those studies were associated with an overall
producing cells (F). Analysis of the Geometric Mean of Fluorescence Intensity of IFNc, TNFa or IL-2; produced by different populations of LACK-
specific CD4
+ T cells isolated from animals that received heterologous vaccination with DNA-LACK/MVA-LACK. Data is representative of two
independent experiments.
doi:10.1371/journal.pone.0038859.g001
Immune Response Elicited by DNA-LACK/MVA-LACK
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e38859Figure 2. Memory immune response induced in mice immunized with the LACK vectors. A. Analysis of the antigen-specific IFNc secreting
cells by splenocytes measured by ELISPOT 53 days after the booster. B. Analysis of the total magnitude of effector memory (CD62L
2 CD44
+) LACK-
specific CD4 and CD8
+ T cell responses in splenocytes re-stimulated with LACK protein. Among the lymphocyte population, T cells were gated and
analyzed for IFNc, TNFa and/or IL-2 production. Cytokine production by effector memory (CD62L
2 CD44
+) LACK-specific CD8
+ T cells (C), effector
memory (CD62L
2 CD44
+) LACK-specific CD4
+ T cells (D) and effector memory (CD62L
2 CD44
+) LACK157–173 peptide-specific CD4
+ T cells (E). The
different combinations of cytokines are indicated on the x-axis; percentages T cells producing any cytokine are indicated on the y-axis. The different
pies show the quality of the response measured as the relative quantity of single, double or triple cytokine producing cells. Data is representative of
two independent experiments.
doi:10.1371/journal.pone.0038859.g002
Immune Response Elicited by DNA-LACK/MVA-LACK
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e38859Figure 3. Immune response triggered in immunized mice after parasite challenge. A. Analysis of the antigen-specific IFNc secreting cells
by splenocytes measured by ELISPOT 10 days after the challenge. B. Analysis of the total magnitude of CD4
+ and CD8
+ T cell responses in splenocytes
re-stimulated with LACK protein. Among the lymphocyte population, T cells were gated and analyzed for IFNc, TNFa and/or IL-2 production. Cytokine
production by LACK-specific CD4
+ T cells (C), LACK157–173 peptide–specific CD4
+ T cells (D), LACK157–173–specific CD8
+ T cells (E). The different
combinations of cytokines are indicated on the x-axis; percentages T cells producing any cytokine are indicated on the y-axis. The different pies show
Immune Response Elicited by DNA-LACK/MVA-LACK
PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e38859Th1 response against LACK antigen [19,27]. Thus, vaccinia virus
worked as a strong adjuvant and delivery vector altogether,
modifying natural Th2-IL-4 response to LACK antigen dependent
of Vb4V a8 CD4
+ T cells [7].
BALB/c mice develop a polarized and fatal Th2 immune
response to subcutaneous Leishmania major infection due principally
to the high immunogenicity of LACK antigen [5], in particular to
the immunogenicity of the LACK157–173 CD4
+-restricted peptide
[22,28,29,30]. Here we studied in detail the different T cell
populations activated in BALB/c mice using the DNA/MVA
vaccination approach, since Th1 responses driven mainly by
CD4
+ and CD8
+ T cells have a major role in the immunology of
cutaneus and visceral leishmaniasis [9]. We found that the
adaptive immune response elicited by this protocol is characterized
by a marked Th1 phenotype to the LACK antigen, represented by
a low frequency but high quality CD4
+ T cells against LACK
the quality of the response measured as the relative quantity of single, double or triple cytokine producing cells. Data is representative of two
independent experiments.
doi:10.1371/journal.pone.0038859.g003
Figure 4. Analysis of humoral and cellular responses triggered by the MVA vector. A. IgG total antibodies at different points post-
immunization where measured by ELISA using extracts of BSC40 cells infected with VACV. B. Analysis of the E3-specific IFNc secreting cells by
splenocytes measured by ELISPOT 11 days after the booster (prechallenge), 10 days after experimental challenge (postchallenge) or 53 days after the
booster (memory). Among the lymphocyte population, T cells were gated and analyzed for IFNc, TNFa and/or IL-2 production. C. Cytokine production
by E3-specific CD8
+ T cells 11 or 53 days after the booster.
doi:10.1371/journal.pone.0038859.g004
Immune Response Elicited by DNA-LACK/MVA-LACK
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75% of those LACK-specific or LACK157–173 peptide-specific T
cells expressing two or more cytokines. The importance of these
multifunctional T cells might be explained by the fact that each
single cell is capable of a broader repertoire of functions. These
polyfunctional cells also showed an increase of the Mean
Fluorescence Intensity (MFI) for IFNc, TNFa and IL-2, meaning
that the high quality profile of these cells also reflect higher levels
of cytokine secretion on a per-cell basis. This last phenomenon was
also observed in post-challenge and memory studies (not shown).
Moreover, we have seen that the parasite at early stages of the
infection in vaccinated animals boosted both CD8
+ and CD4
+ T
cells. LACK-specific CD8
+ T cells producing altogether IFNc and
TNFa was observed. As differences in the profile of cytokines
produced by individual cells have profound implications for their
capacity to mediate effector function, this specific population is
particularly relevant because both cytokines synergize in their
capacity to mediate killing of leishmania through the induction of
NO [31,32]. This increase in CD8
+ T cells is also noticed 4 weeks
after experimental challenge with L. major. Although CD4
+ T cells
maintain magnitude and quality, there is an increment in CD8
+ T
cells magnitude represented in a 70% of cells secreting IFNc.
We also observed that the resulting memory population 53 days
after booster is mostly represented by high quality effector CD4
+ T
cells, with around 40% of CD44
+ CD62L
2 T cells secreting two or
more cytokines.
From a vaccine point of view it was relevant to find at the
memory stage an increase in the production of TNFa in both
CD8
+ and CD4
+ LACK-specific effector memory T cells (Fig. 2),
as TNFa has important stimulatory effects on macrophage killing
activity [33], and its production has been shown to correlate with
protection [34,35]. It has been also demonstrated that CD4
+ T
cells that expresses IFNc and TNFa play an important role in
therapy against leishmaniasis [36]. It is important to point out that
mice deficient in this cytokine failed in controlling cutaneus and
visceral infection produced by Leishmania [37,38].
We further confirm that the immune cells were of effector
memory phenotype since the antigen-specific CD4
+ and CD8
+ T
cell populations were mainly CD62L
2CD127
+. These results
agree with recent publications that showed that in heterologous
prime-boost vaccination regimen, CD8
+ effector memory cells are
the most relevant cells for long term protective immunity against
parasites [39,40], but also suggest that high quality effector
memory CD4 T cells might play a relevant role in protection.
Darrah et all observed that immunization withvarious vaccine
formulations with adenovirus vectors encoding specific L. major
antigen (Leish-111f) or after primary infection with L. major,
induced the expansion of multifunctional CD4
+ T cells that secrete
IFNc, IL-2 and TNFa which strongly correlate with protection
against subsequent challenge [15]. These authors also showed
increased MFI for IFNc and TNFa. Recently, it has been also
reported the presence of this high quality, multifunctional CD4
+ T
cells in peripheral blood mononuclear cells of patients that healed
American cutaneus leishmaniasis, and the same phenomenon was
observed in the MFI for IFNc, IL-2 and TNFa, thus supporting
the significance of our findings [41]. In fact, in our DNA-LACK/
MVA-LACK system we also observed multifunctional CD4+ T
cells that secrete IFNc, IL-2 and TNFa, but in addition we
obtained CD8
+ T cell responses which are also polyfunctional.
The CD8
+ T cells could be driven by the MVA vector, as the
responses to a VACV antigen are mainly CD8
+ T cells (Fig. 4C–
D).
In conclusion, these results demonstrate that the expression of
LACK protein in a DNA prime/MVA boost regimen can lead to
the proliferation of a LACK-specific high quality subset of
adaptive and memory CD4
+ T cells with broad functionality that
secrete a spectrum of Th1 cytokines. The heterologous vaccination
also induced high quality LACK-specific CD4
+ and CD8
+ T cell
effector memory populations. Anti-vector responses were largely
CD8-mediated. The CD4
+ T cell cytokine response to LACK is
compatible with the findings that this T cell profile can be crucial
in a protective response [42]. Thus, the immune parameters
triggered by the combined vaccination DNA-LACK/MVA-
LACK protocol are likely to be relevant in the protection
conferred against leishmaniasis that we have previously described
in mice and dogs using the same protocol.
Materials and Methods
Ethics Statement
The Ethical Committee of Animal Experimentation (CEEA-
CNB) of Centro Nacional de Biotecnologı ´a (CNB-CSIC) approved
the animal studies in accordance with national and international
guidelines and with the Royal Decree (RD 1201/2005). Permit
number: 080011.
Parasite strains and animals
L. major (WHOM/IR/-173) was a kind gift from Dr Nicholas
Glaichenhaus (CNSR, Valbonne, France). Promastigotes were
cultured at 27uC in Schneider’s medium (Gibco BRL, UK),
supplemented with 20% fetal calf serum (FCS, Gibco BRL, UK)
and antibiotics. The virulence of the strain was preserved by
periodic passage through BALB/c mice. Frozen stocks grown in
culture until the stationary phase were used for the experiments. In
order to purify only infective metacyclic promastigotes stationary
phase cultures were resuspended in endotoxin-free phosphate
buffered saline (PBS) at a final concentration of 1–5610
8
promastigotes/ml and treated with 10 mg/ml of Peanut Agglu-
tinin (PNA). After centrifugation at 1000 rpm, metacyclic
promastigotes were collected from the supernatant, washed twice
with PBS and resuspended in the same buffer for inoculation. All
mice used in this study were female BALB/c mice ranging from 6
to 8 weeks of age purchased from Harlan (IN, USA) and housed in
the Animal Facility of the Centro Nacional de Biotecnologı ´a-CSIC
(Madrid, Spain) under pathogen-free conditions.
Cells, plasmids and viruses
Cells were maintained in a humidified air 5% CO2 atmosphere
at 37uC. Primary chicken embryo fibroblasts (CEF) were obtained
from pathogen-free (SPF) 11-day-old eggs (Intervet, Salamanca,
Spain) and were grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% FCS.
The mammalian expression plasmid vector pCI-neo-LACK,
named here as DNA-LACK, was previously described [19]. The
empty plasmid pCI-neo (Promega) was used as control (DNAw).
Both constructs were purified using the Qiagen plasmid purifica-
tion kit (Qiagen).
The viruses used in this study included the highly attenuated
Modified Vaccinia Ankara strain (MVA-wt, obtained at passage
586) or the recombinant MVA expressing the Leishmania major
LACK antigen in the viral HA locus, lacking a selectable marker
(MVA-LACK). All viruses were grown in CEF cells. Purification
and titration of viruses was performed as previosly described
[43,44].
Plasmids and viruses were diluted for inoculation in endotoxin-
free PBS.
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L. infantum LACK protein was expressed as a fusion protein with
a histidine tag at the N-terminal end using the Escherichia coli strain
BL21 pLysS transformed with the plasmid pRSET-B-LACK [45],
which allows its purification by affinity chromatography on a Ni
2+
column. Bacteria were grown in the presence of antibiotic and the
expression of the protein was induced by the addition of isopropyl
thio-b-D-galactoside (IPTG) at a final concentration of 0.5 mM.
Cultures were centrifuged (5000 rpm 15 min) and resuspended in
Lysis Buffer (8 M urea, 50 mM Tris-HCL pH 8, 500 mM NaCl)
and incubated 1 hour while being mixed in over-end in a tube
rotator at 4uC. After 30 min centrifugation at 11000 rpm
supernatant was incubated 1 hour while being mixed in over-
end in a tube rotator at 4uC with 2 ml of equilibrated ProBond
Nickel-Chelating Resin (Invitrogen). Beads were washed three
times with Wash Buffer (8 M urea, 50 mM Tris-HCL pH 8,
500 mM NaCl, 10 mM imidazol) and elution was done increasing
Imidazol final concentration up to 200 mM. PD10 Desalting
Columns (GE Healthcare) were used to finally keep LACK protein
in saline for in vitro studies. Protein preparations were analysed by
Coomassie stain and Western-blot.
Leishmania soluble antigen (LSA) was prepared from late
stationary phase L. major promastigotes. Cultures were collected
and resuspended in 10 ml of phosphate buffer saline (PBS). After
five freeze–thaw cycles, the suspension was centrifuged at
3000 rpm and the supernatant was collected in 1 ml aliquots.
The protein concentrations were estimated using the BCA method
(Pierce, Rockford, IL). The protein purity and concentration was
determined by SDS-PAGE and BCA method, respectively (Pierce,
Rockford, IL).
LACK157–173 peptide (FSPSLEHPIVVSGSWDN) was chemi-
cally synthesized at Proteomic Service, CNB.
LACK and LSA were sonicated during three cycles of 1 min
each at 30% output power (Sonifier Cell Disrupter, Heat Systems
Ultrasonic, Inc.) when used as stimulus in the ELISPOT and ICS
assays.
Immunization and infectious challenge
BALB/c mice, 6–8 weeks of age, were primed intradermally
(i.d.) in the abdomen with 100 mg of DNA-LACK or DNAw in
100 ml volume per mouse. At day 14 mice were boosted
intraperitoneally (i.p.) with MVA-LACK or MVA-wt
(2610
7 PFU/mouse) and PBS as control. Eleven days after
boosting (day 25), three or five mice per group were sacrificed
and sera and spleens were collected to analyze adaptive immune
responses. Three weeks after boosting (day 46) five animals per
group were challenged subcutaneously in the right hind footpad
with 5610
4 metacyclic PNA-purified L. major promastigotes
resuspended in 10 ml using BD Micro-Fine (BD Consumer
Healthcare) 0,5 ml 30G needles. Mice were sacrificed 10 days
post-challenge, and sera and spleens were harvested for immuno-
logical studies. For the memory studies, the remaining 5
vaccinated animals were sacrificed 53 days after boosting and
sera and spleens were harvested for immunological studies. Two
independent experiments were performed.
Antibody measurement by ELISA
Presence of LACK-specific IgGs, IgG1 and IgG2a in serum
samples, was assessed as previously described [26]. Serum from
individual mice was reacted at 1:100 dilution in triplicates against
10 mg/ml of extracts obtained from epithelial monkey kidney
BSC40 cells infected with vaccinia virus (VACV) strain WR and
treated with 0.5% NP40.
Evaluation of specific T cells by the ELISPOT assay
The enzyme-linked immunospot (ELISPOT) assay to detect
antigen-specific T cells was performed as described previously
[26]. Briefly, 96-well nitrocellulose plates were coated with 6 mg/
ml of anti-mouse IFNc monoclonal antibody R4-6A2 (PharMin-
gen, San Diego, CA) in 75 ml of PBS. Following overnight
incubation at room temperature, the wells were washed three
times with RPMI 1640 and blocked with complete medium
supplemented with 10% FCS during 1 h at 37uC. Triplicate
cultures of erythrocyte-depleted spleen cells were prepared from
immunized mouse splenocytes in two dilutions, 10
6 and 5610
5/
well. Splenocytes were used as a source of antigen presenting cells.
The number of IFNc secreting cells specific for the different
antigens was evaluated by pulsing the splenocytes with either,
25 mg/ml of sonicated recombinant LACK protein, 2 mg/ml of
LACK157–173 peptide, 10 mg/ml of LSA or 10 mg/ml of E3
peptide. Plates were incubated for 18 h at 37uC with a 5% CO2
atmosphere, washed extensively with PBS–0.05% Tween (PBS-T)
and incubated for 2 h at room temperature with 2 mgo f
biotinylated anti-mouse IFNc monoclonal antibody XMG1.2
(PharMingen, San Diego, CA) per ml in PBS-T. Afterwards, plates
were washed with PBS-T and 100 ml of peroxidase-labeled avidin
(PharMingen, San Diego, CA) at a 1/800 dilution in PBS-T was
added to each well. After 1 h of incubation at room temperature,
wells were washed with PBS-T and PBS. The spots were
developed by the addition of 3,39-diaminobenzidine tetrahy-
drochloride substrate (1 mg/ml) (Sigma, St. Louis, MO) in 50 mM
Tris–HCl, pH 7.5 containing 0.015% hydrogen peroxide and
were counted with an AID ELISPOT reader system (Vitro).
Intracellular Cytokine Staining assay (ICS)
The phenotypes of responding T cells were analyzed by ICS
and fluorescence-activated cell sorting analysis as described
elsewhere [46]. After an overnight rest, 5610
6 splenocytes
(depleted of red blood cells) were stimulated with 25 mg/ml of
LACK protein, 2 mg/ml of LACK157–173 peptide or 10 mg/ml of
E3 peptide during 2 hours and left 4 hours in RPMI 1640
supplemented with 10% FCS and containing 1 ml/well Golgiplug
(BD Biosciences) to inhibit cytokine secretion. Stimulation with
LSA was performed overnight and as with the other stimulus
splenocytes remained the last 4 hours in RPMI 1640 supplemen-
ted with 10% FCS and containing 1 ml/well Golgiplug (BD
Biosciences) to inhibit cytokine secretion. After stimulation, cells
were washed, stained for the surface markers, fixed, permeabilized
using the BD Cytofix/Cytoperm
TM Kit (Becton Dickinson) and
stained intracellularly using the appropriate fluorochromes. To
analyze the adaptive and post-challenge immune responses, the
following fluorochrome-conjugated antibodies were used: CD3-
FITC, CD4-Alexa 700, CD8-PerCP, IL-2-PE, IFNc-APC and
TNFa-PECy-7. For memory analyses, the following antibodies
were used: CD4-Alexa 700, CD8-V500, CD62L-FITC, CD44-
SPRD, CD127-PECy5.5, IFNc-PECy-7, TNFa-PE and IL-2-
APC. All antibodies were from BD Biosciences. Cells were
acquired using an LSRII flow cytometer (Becton Dickinson)
equipped with a high throughput system. The number of events
ranged between 10
5 and 10
6. Dead cells were excluded using the
violet LIVE/DEAD stain kit (Invitrogen). Lymphocytes were
gated on a forward scatter area versus side scatter area pseudo-
color dot plot. To analyze the adaptive immune responses, CD4
+
and CD8
+ events (gated previously on CD3
+ cells) were gated
versus IFNc, TNFa and IL-2, and then combined together using
the boolean operator. For memory analyses, CD4
+ and CD8
+
events were gated versus CD44 and CD62L or CD62L and
CD127 to analyze the memory phenotype. IFNc, TNFa and IL-2
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combined together using the boolean operator. Sample analysis
was performed using FlowJo version 8.5.3 (Tree Star, Ashland,
OR).
Statistical analysis
Statistical significance (p,0.05 (*), p,0.005 (**) or p,0.001
(***)) of differences between immunization groups of mice was
determined by Student’s t-test.
For the statistical analysis of ICS data we used a novel approach
that corrects measurements for the medium response (RPMI) and
at the same time allows the calculation of confidence intervals and
p-values of hypothesis tests [47,48].
The data analysis program, Simplified Presentation of In-
credibly Complex Evaluations (SPICE, version 4.1.5, Mario
Roederer, Vaccine Research Center, NIAID, NIH), was used to
analyze and generate graphical representations of T cell responses
detected by polychromatic flow citometry. All values used for
analyzing proportionate representation of responses are back-
ground-subtracted.
Supporting Information
Figure S1 Analysis of the phenotype of memory antigen-
specific CD4
+ and CD8
+ T cells in splenocytes re-
stimulated with LACK protein or LACK peptide. Memory
T cells were classified as central memory (CD62L
+CD127
+),
effector memory (CD62L
2 CD127
+) or effector (CD62L
2
CD127
2). Percentages represent the frequencies of T cells
secreting IFNc and/or TNFa and/or IL-2.
(TIF)
Figure S2 Cytokine production by antigen-specific T
cells 10 days after parasite challenge. (A) Analysis of the
total magnitude of CD4
+ and CD8
+ T cell responses in splenocytes
re-stimulated with LSA. Among the lymphocyte population, T
cells were gated and analyzed for IFNc, TNFa and/or IL-2
production. Cytokine production by LSA-specific CD8
+ T cells (B)
or LSA-specific CD4
+ T cells (C). The different combinations of
cytokines are indicated on the x-axis; percentages of T cells
producing any cytokine are indicated on the y-axis. The different
pies show the quality of the response measured as the relative
quantity of single, double or triple cytokine producing cells. Data is
representative of two independent experiments.
(TIF)
Figure S3 Immune profile 4 weeks after parasite
challenge. A. Analysis of the antigen-specific IFNc secreting
cells by splenocytes measured by ELISPOT. B. Analysis of the
total magnitude of CD4
+ and CD8
+ T cell responses in splenocytes
re-stimulated with LACK protein. Among the lymphocyte
population, T cells were gated and analyzed for IFNc, TNFa
and IL-2 production. Cytokine production by LACK-specific
CD4
+ T cells (C) and LACK-specific CD8
+ T cells (D). The
different combinations of cytokines are indicated on the x-axis;
percentages of T cells producing any cytokine are indicated on the
y-axis. The different pies show the quality of the response
measured as the relative quantity of single, double or triple
cytokine producing cells.
(TIF)
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